| Previous Close | 31.0500 |
| Open | 31.2700 |
| Bid | 32.3200 x 700 |
| Ask | 32.3300 x 3300 |
| Day's Range | 31.2100 - 32.5000 |
| 52 Week Range | 27.6000 - 56.4400 |
| Volume | 4,594,647 |
| Avg. Volume | 7,457,859 |
| Market Cap | 33.15B |
| Beta | 0.52 |
| PE Ratio (TTM) | 416.54 |
| EPS (TTM) | 0.08 |
| Earnings Date | N/A |
| Dividend & Yield | 1.36 (4.34%) |
| Ex-Dividend Date | 2017-06-01 |
| 1y Target Est | 36.83 |
- Zacks•2 hours ago
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
- Reuters•18 hours ago
GSK wins $235 million from Teva in Coreg patent trial
A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. A federal jury in Wilmington, Delaware on Tuesday found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure. The jury rejected Teva's contention that the patent was invalid.
- Reuters•yesterday
Israeli credit card firm Isracard names outgoing Teva CFO as chairman
Israel's biggest credit card company Isracard on Wednesday named Eyal Desheh, the outgoing chief financial officer of Teva Pharmaceutical Industries , as its new chairman. Teva in April said Desheh would step down at end-June after nearly a decade in the job, the second top official to resign from the Israel-based company this year. Isracard is a unit of Bank Hapoalim, Israel's largest lender.
